FDA updates CRO & sponsor inspection guidance

By Nick Taylor

- Last updated on GMT

Related tags: Clinical trial

The FDA has revised guidance on how its personnel conduct inspections of CROs and sponsors in light of technological advances.

Guidance on the topic was first issued in 2001 but since then clinical research and outsourcing have evolved. Revisions to the document cover industry shifts and technological advances, such as the rise of electronic records, but the focus and goals of the document remain unchanged.

These regulations establish specific responsibilities of sponsors for ensuring the proper conduct of clinical studies for submission to FDA (US Food and Drug Administration) and the protection of the rights and welfare of subjects involved in clinical studies​”, says the guidance.

While retaining this focus the FDA compliance program guidance manual (CPGM) for sponsors, contract research organisations (CRO), and monitors​ has been revised with the addition of new sections and deletion of others.

For instance, electronic records and signatures are now covered by the guidance. Although this is new the goal is unchanged, with regulatory requirements staying the same “whether clinical data are captured on paper, electronically, or using a hybrid approach​”.

Submission of information to ClinicalTrials.gov is another change. Inspectors must now determine if studies were registered on ClinicalTrials.gov, who entered the information, and whether primary and secondary outcome measures are listed.

Global regulation

Clinical trials are increasingly conducted outside the US and the FDA guidance accounts for this change. Overseas trials must be compliant with good clinical practice (GCP), says the guidance, and the FDA must be able to validate data through an on-site inspection if deemed necessary.

Globalisation has advanced alongside multisite trials and both are addressed by the guidance. “With the prevalence of multisite clinical trials, traditional monitoring techniques – early and frequent on-site visits at all clinical sites – have become resource intensive​”, says the guidance.

Other areas addressed by the guidance include: what to do when fraud is suspected; financial disclosure from investigators; and how to investigate whether emergency research followed guidelines.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more